|Last Price||Today's Change||52-Week Range||Trading Volume|
|51.48||-0.99 (-1.89%)||41.68 - 54.00||1.9 million (Below Avg)|
Market data as of 4:01PM 06/19/13. Quotes are delayed by at least 15 min.
Renaissance and GlaxoSmithKline Agree to a Transfer of Nine Products
06/03/2013 12:04 PM ET
Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets, approved by FDA as single-agent therapies
05/29/2013 5:24 PM ET